Segment Information

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Segment Information

NOTE 14 – SEGMENT INFORMATION

Information related to the Company’s reportable operating business segments is shown below. The Company’s reportable segments are reported in a manner consistent with the way management evaluates the businesses. The Company identifies its reportable business segments based on differences in products and services. The accounting policies of the business segments are the same as those described in the summary of significant accounting policies. The Company has identified the following business segments:

•  The Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry and includes consolidated reporting of TI Services, the Company’s 50/50 joint venture with RadQual.

•  The Cobalt Products segment includes management of a cobalt irradiation contract, fabrication of cobalt capsules for teletherapy or irradiation devices, and recycling of expended cobalt sources.

•  The Radiochemical Products segment includes production and distribution of various isotopically pure radiochemicals for medical, industrial, or research applications. These products are either directly produced by the Company or are purchased in bulk from other producers and distributed by the Company in customized packages and chemical forms tailored to customer and market demands. Iodine-131 is the predominant radiochemical sold in this segment and an abbreviated new Drug Application (aNDA) has been submitted to the U.S. Food and Drug Administration to market this as a generic drug product upon approval.

•  The Fluorine Products segment historically involved the production of small scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. During 2013, these testing activities were completed and the pilot plant facility was closed. The Company has developed or acquired all patent rights to these processes. Future work in this segment will involve license support and, as financing permits, further work related to the de-conversion facility.

•  The Radiological Services segment concerns a wide array of miscellaneous services that consists of gemstone processing and field services that include source installation, removal, and radiation device decommissioning.

•  The Transportation segment provides transportation services for the Company’s products and offers “for hire” transportation services of hazardous and non-hazardous cargo materials.

The following presents certain segment information as of and for the years ended December 31, 2016 and 2015:

Sale of product	2016		2015
Radiochemical products	$	1,708,120	$	1,698,475
Cobalt products		859,034		929,970
Nuclear medicine standards		3,093,295		3,135,094
Radiological services		769,702		1,181,957
Fluorine products		-		-
Transportation		121,998		116,700
Total segments		6,552,149		7,062,196
Corporate revenue		-		-
Total consolidated	$	6,552,149	$	7,062,196
Depreciation and amortization	2016		2015
Radiochemical products	$	6,995	$	6,913
Cobalt products		43,802		41,617
Nuclear medicine standards		12,888		15,818
Radiological services		34,019		25,588
Fluorine products		112,053		110,692
Transportation		10,429		4,442
Total segments		220,186		205,070
Corporate depreciation and amortization		6,670		6,104
Total consolidated	$	226,856	$	211,174
Segment income (loss)	2016		2015
Radiochemical products	$	355,448	$	336,662
Cobalt products		472,890		344,073
Nuclear medicine standards		680,004		483,169
Radiological services		371,228		568,192
Fluorine products		(378,705)		(356,492)
Transportation		(34,374)		(26,773)
Total segments		1,466,491		1,348,831
Corporate loss		(3,345,603)		(3,167,056)
Total consolidated	$	(1,879,112)	$	(1,818,225)
Expenditures for segment assets	2016		2015
Radiochemical products	$	-	$	2,331
Cobalt products		-		4,578
Nuclear medicine standards		12,682		26,817
Radiological services		56,677		24,642
Fluorine products		11,170		20,403
Transportation		53,631		-
Total segments		134,160		78,771
Corporate purchases		6,956		14,056
Total consolidated	$	141,116	$	92,827
Segment assets	2016		2015
Radiochemical products	$	267,920	$	212,988
Cobalt products		1,414,240		934,781
Nuclear medicine standards		502,361		626,615
Radiological services		171,354		502,445
Fluorine products		5,801,627		5,904,150
Transportation		49,706		1,642
Total segments		8,207,208		8,182,621
Corporate assets		3,172,057		3,060,606
Total consolidated	$	11,379,265	$	11,243,227